Bayer is reshaping how procurement influences environmental and social outcomes, using sourcing decisions to accelerate emissions reductions, expand access to medicine, and strengthen food-system resilience. As global suppliers face rising expectations tied to the UN Sustainable Development Goals and Europe’s new corporate sustainability directives, the company is tightening the link between procurement policy, science-based targets and real-world impact.
Turning Supplier Selection Into a Climate Mitigation Lever
Bayer has set out a long-term plan to reach net-zero greenhouse gas emissions across its value chain by 2050 or earlier, with an interim commitment to cut Scope 1 and 2 emissions 42% by 2029 from a 2019 baseline. Much of that progress is expected to come from procurement, which is being asked to shift all purchased electricity to renewable sources and apply stricter criteria to how green energy is acquired.
Rather than relying on certificates alone, the company emphasizes new-build renewable projects, particularly wind and solar, and prefers power generated close to its operational sites to reduce grid losses and improve reliability. This mirrors a broader market trend: recent data shows multinational buyers increasingly using long-term power purchase agreements to secure renewable capacity and lock in price stability as energy volatility persists across Europe and Asia.
The environmental measures extend inside Bayer’s facilities as well. Procurement is coordinating investments in high-efficiency ventilation systems, low-emissions heating solutions, and climate-neutral technologies such as geothermal systems. These upgrades complement its supply chain-wide decarbonization efforts, which are being shaped by the EU’s Corporate Sustainability Due Diligence Directive (CS3D). The regulation is prompting companies to evaluate how procurement can more directly influence emissions reductions and environmental performance deep into supplier networks.
“Health for all, hunger for none” remains a touchstone for Bayer’s strategy, but the operational shift now hinges on how sourcing teams prioritize suppliers, energy inputs, and technologies that materially support emissions goals.
Expanding Healthcare Access Through Targeted Sourcing and Pricing Models
Bayer is also using its global supply network to widen access to essential medicines and consumer health products. With sizeable gaps in healthcare availability across low and middle-income countries, the company’s access strategy focuses on product affordability, resilient distribution, and pricing models designed to reach more patients.
The portfolio spans cardiology, women’s health, ophthalmology and radiology, and the company continues to scale contraceptive availability. It aims to supply 100 million women in lower-income countries with modern contraceptives by 2030, having already reached 51 million by 2024, according to publicly shared data. Alongside this, Bayer intends to support 100 million people annually in underserved communities with self-care products that reduce reliance on strained healthcare systems.
A flexible pricing approach enables local teams to adjust to economic conditions and negotiate in ways that maximize reach without compromising product reliability. This blend of procurement discipline, supply chain design, and market-access strategy reflects a growing trend in the sector: using supply models not only to manage cost but to close structural gaps in global health equity.
A Shift Toward Measurable Procurement Influence
Over the next several years, one of the most consequential shifts will be the pressure on companies to show quantifiable supplier-level improvements, not simply corporate-level commitments. According to recent industry assessments, regulators and investors are increasingly asking how procurement decisions translate into verified emissions reductions, tighter material stewardship, and more resilient supplier ecosystems. This signals a more rigorous era: one in which procurement’s credibility will rest on the integrity of its data and the traceability of its outcomes, not the volume of its pledges.